Current impact of natural products in the discovery of anticancer drugs

Annales pharmaceutiques françaises
C Monneret

Abstract

Since the middle of 1990s, the development of combinatorial chemistry along with the high throughput screening have led to some lack of interest for natural products from the pharmaceutical industry. Moreover, purification and optimization of natural compounds are very often difficult and animal experimentations need enough supply of natural sources or alternatively need sophisticated total synthesis. In oncology, this increased disinterest was also closely connected with the rapid expansion of monoclonal antibodies and synthetic protein kinase inhibitors. However since 2005, with the approval of five new drugs by the FDA (trabectedin, ixabepilone, temsirolimus, everolimus and Vinflunine), it appears that natural products are still present as direct or indirect sources of drugs. On the other hand, a third generation of natural product has arisen, which relies upon bioengineering using genetically altered producer organisms. This is particularly true of the polyketides where bioengineering harnesses their natural flexibility to expand their structural diversity. Several programs are going on to produce antibiotics, anticancer drugs or immunosuppressant. This combinatorial approach makes drug discovery by bioengineering complemen...Continue Reading

References

Mar 1, 1993·The American Journal of Medicine·D M Goldenberg
Jan 3, 2001·Kidney International·R N SaundersM L Nicholson
Jun 5, 2003·Nature Biotechnology·Svetlana O DoroninaPeter D Senter
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kam Fai TseWilliam J LaRochelle
Mar 11, 2006·Investigational New Drugs·D GoldsteinM Byrne
Jul 11, 2006·Journal of Medicinal Chemistry·Wayne C WiddisonRavi V J Chari
Jul 18, 2006·Current Topics in Medicinal Chemistry·Len Neckers
Aug 3, 2006·Nature Reviews. Drug Discovery·Sandrine FaivreEric Raymond
Oct 17, 2006·Oncogene·J B Easton, P J Houghton
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey A SosmanMichael B Atkins
Oct 2, 2007·Current Opinion in Oncology·Shuo Ma, Steven T Rosen
Dec 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shanu ModiClifford A Hudis
Mar 14, 2008·Assay and Drug Development Technologies·David Newman
Apr 2, 2008·Expert Opinion on Pharmacotherapy·Alfonso Quintás-Cardama, Jorge Cortes
May 8, 2008·The Journal of Organic Chemistry·David G I Kingston
Aug 14, 2008·Expert Review of Anticancer Therapy·Francesco Atzori, Monica Fornier
Aug 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ting-Chao ChouSamuel J Danishefsky
Oct 9, 2008·Current Opinion in Oncology·Mary Cianfrocca
Nov 18, 2008·Cancer Research·Gail D Lewis PhillipsMark X Sliwkowski
Nov 22, 2008·Bioorganic & Medicinal Chemistry·William FenicalBarbara C Potts
Dec 17, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·H MaedaJ Daruwalla
Dec 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francis Y F LeeRobert Kramer
Dec 20, 2008·Nature Reviews. Drug Discovery·Tadeusz F MolinskiJonel P Saludes
Dec 31, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C SessaL Gianni
Jan 14, 2009·Molecular Cancer Therapeutics·Charles DumontetFrancis F Y Lee
Jan 24, 2009·Biochemical Pharmacology·Christian Bailly
Feb 5, 2009·Molecular Cancer Therapeutics·Claudia ForniRoberto Mantovani
Feb 26, 2009·Natural Product Reports·Carmen Cuevas, Andrés Francesch
May 6, 2009·Current Opinion in Chemical Biology·Peter D Senter
May 9, 2009·Chemical Reviews·Gordon M CraggDavid J Newman
May 16, 2009·Current Cancer Drug Targets·B C BrowneN O'Donovan
May 30, 2009·Leukemia & Lymphoma·Mehul P Patel, Asher A Chanan-Khan
Jul 17, 2009·Expert Opinion on Investigational Drugs·Otto Metzger-FilhoAwada Ahmad
Aug 19, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntHans von der Maase
Aug 27, 2009·Biologics : Targets & Therapy·Shannon Puhalla, Adam Brufsky
Jan 19, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Cristina SuárezJoan Carles

❮ Previous
Next ❯

Citations

Mar 14, 2012·Marine Drugs·Marina Gordaliza
May 31, 2012·Médecine sciences : M/S·Pierre P J Da Silva, Laurent Meijer
Jun 24, 2010·Annales pharmaceutiques françaises·C Monneret
Apr 25, 2017·Critical Reviews in Biotechnology·Kashyap Kumar DubeyPratyoosh Shukla
Mar 9, 2021·Journal of Enzyme Inhibition and Medicinal Chemistry·Xiangge TianXiaochi Ma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomaterial Engineering

Advances in biomaterial engineering have permitted the development of sophisticated drug-releasing materials with a biomimetic 3D support that allow a better control of the microenvironment of transplanted cells. Here is the latest research.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

© 2021 Meta ULC. All rights reserved